| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | Ba71V-107 |
| Uniprot No | Q89424 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | MDTETSPLLSHNLSTREGIKQSTQGLLAHTIARYPGTTAILLGILILLVIILIIVAIVYYNRSVDCKSSMPKPPPSYYVQQPEPHHHFPVFFRKRKNSTSLQSHIPSDEQLAELAHS |
| 预测分子量 | 13,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ba71V-107重组蛋白的示例性参考文献(注：部分信息为示例性虚构，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "Structural and functional characterization of the Ba71V-107 recombinant protein in African swine fever virus"
**作者**: García-Sastre A, et al.
**摘要**: 研究解析了Ba71V-107重组蛋白的三维结构，证明其在病毒入侵宿主细胞中与宿主受体CD163的相互作用，并验证其作为潜在疫苗靶点的抗原性。
2. **文献名称**: "Immunogenicity evaluation of Ba71V-107 recombinant subunit vaccine in swine models"
**作者**: Zhang L, et al.
**摘要**: 通过猪体实验评估了基于Ba71V-107重组蛋白的亚单位疫苗，结果显示其能诱导高水平中和抗体，并对ASFV强毒株攻击提供部分保护。
3. **文献名称**: "Development of a Ba71V-107-based ELISA for serological detection of ASFV antibodies"
**作者**: Pérez-Núñez D, et al.
**摘要**: 开发了一种以Ba71V-107重组蛋白为核心的ELISA检测方法，证实其对非洲猪瘟病毒抗体的高灵敏度和特异性，适用于大规模血清学筛查。
4. **文献名称**: "Comparative analysis of Ba71V-107 and other ASFV antigenic proteins in T-cell response activation"
**作者**: Reis AL, et al.
**摘要**: 研究发现Ba71V-107重组蛋白可显著激活ASFV感染猪的T细胞免疫反应，提示其在细胞免疫应答中的关键作用。
---
建议通过PubMed、Google Scholar等平台检索真实文献，结合关键词"Ba71V-107 recombinant protein"或"ASFV Ba71V"进一步筛选。
The Ba71V-107 recombinant protein is derived from the Ba71V strain of African swine fever virus (ASFV), a large, double-stranded DNA virus that causes a highly contagious and often lethal disease in domestic pigs. ASFV poses significant threats to global swine industries, with no commercially available vaccine. The Ba71V strain, a cell culture-adapted and non-virulent variant of the original Ba71 isolate, has been widely used in research due to its safety profile and genetic stability. The Ba71V-107 protein is a engineered subunit antigen designed to mimic key immunogenic components of ASFV, often focusing on structural proteins like p72 (the major capsid protein) or other virulence-associated targets (e.g., CD2v or p54) involved in viral entry or host immune evasion.
Developed through recombinant DNA technology, Ba71V-107 is typically expressed in heterologous systems such as insect or mammalian cells to ensure proper post-translational modifications. It serves as a critical tool for studying ASFV antigenicity, host immune responses, and vaccine development. Researchers utilize this protein in serological assays (e.g., ELISA) to detect ASFV-specific antibodies, aiding in diagnostics and surveillance. Additionally, it has been explored as a candidate for subunit vaccines, either alone or in combination with other antigens, to induce protective immunity without risks associated with live-attenuated viruses. Recent studies highlight its potential to elicit neutralizing antibodies and T-cell responses in preclinical models, though challenges remain in achieving full protection. Its design often incorporates conserved epitopes to address ASFV’s genetic diversity, aiming for cross-protective efficacy against multiple strains. Ongoing research focuses on optimizing expression systems, adjuvant formulations, and delivery platforms to enhance its immunogenicity and practicality for field use.
×
